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Abstract
This observational, longitudinal retrospective, noncomparative study was designed to assess the persistence and effectiveness of
golimumab as a second anti-tumor necrosis factor (TNF) drug in patients with spondyloarthritis requiring discontinuation from a first
anti-TNF drug.
Data were collected retrospectively for all patients with axial spondyloarthritis or psoriatic arthritis from 20 rheumatology clinics in
Spain who started golimumab as a second anti-TNF drug between January 2013 and December 2015. Golimumab persistence was
assessed with Kaplan-Meier survival analysis, and associated factors were assessed with Cox regression analysis.
210 patients started golimumab as a second anti-TNF drug: 131 with axial spondyloarthritis and 79 with psoriatic arthritis. In axial
spondyloarthritis patients, themean (standard deviation) Bath Ankylosing Spondylitis Disease Activity Index score at baseline was 5.5
(2.1), decreasing to 3.9 (2.0) at month 3 and 3.5 (2.0) at year 1, and remaining stable thereafter. In psoriatic arthritis patients, mean
(standard deviation) baseline Disease Activity Score was 4.0 (1.3), reducing to 2.5 (1.2) at month 3 and to 2.2 (1.3) at year 1.
Corresponding improvements were recorded from baseline in C-reactive protein levels and erythrocyte sedimentation rates. The
probability of persistence of treatment with golimumab was 80% at year 1, 70% at year 2 and 65% at years 3 and year 4, and was
similar in those who had stopped the first anti-TNF due to loss of efficacy or other reasons. Cox regression analysis showed that the
probability of survival with golimumab was higher in patients with higher erythrocyte sedimentation rate, in patients with axial
spondyloarthritis than with psoriatic arthritis, and in those who had discontinued adalimumab as first anti-TNF. Seventy-two patients
(34.3%) discontinued golimumab during follow-up, 50 of them due to lack of efficacy.
In patients with spondyloarthritis requiring discontinuation from a first anti-TNF drug, treatment with golimumab was effective and
showed a high probability of persistence up to 4years of treatment.
Abbreviations: AS = ankylosing spondylitis, BASDAI = Bath Ankylosing Spondylitis Disease Activity Index, CI = confidence
interval, CRP=C-reactive protein, DAS= disease activity score, ESR= erythrocyte sedimentation rate, PsA= psoriatic arthritis, RA=
rheumatoid arthritis, SD = standard deviation, SpA = spondyloarthritis, TNF = tumor necrosis factor.
Keywords: ankylosing spondylitis, anti- tumor necrosis factor, golimumab, psoriatic arthritis, spondyloarthritis, tumor necrosis
factor inhibitor
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Spondyloarthritis (SpA) comprises several rheumatic diseases,
among which the most prevalent and studied are axial
spondyloarthritis (axial SpA) and psoriatic arthritis (PsA). Both
diseases impact patient quality of life at an early age and are
associated with loss of productivity and sick leave.[1] Biological
drugs – initially inhibitors of tumor necrosis factor (TNF) alpha
and later drugs with other mechanisms of action – have changed
the course of these diseases and improved patient quality of life.
For patients with ankylosing spondylitis or nonradiographic
axial SpA, notwithstanding the use of nonsteroidal antiinflam-
matory drugs, the American College of Rheumatology, Spondy-
litis Association of America, and Spondyloarthritis Research and
Treatment Network, and the European League Against Rheu-
matism, recommend the use of anti-TNF drugs;[2,3] for patients
with PsA, biological drugs are recommended when conventional
therapy fails.[4] Whilst anti-TNF drugs are the most frequently
used first biological drugs, the response declines over time in some
patients, requiring a switch to another biological.[3,4]
Most information on the clinical efficacy of anti-TNF drugs is
derived from controlled clinical trials or observational studies in
patients who failed on conventional non-biological therapy and
were naïve to anti-TNF drugs. There is less reported experience of
the mid- and long-term effectiveness of biological drugs as second
biologicals in patients who have discontinued a first anti-TNF
drug.
Golimumab is a human anti-TNF monoclonal antibody with
high affinity binding to soluble and transmembrane TNF.[5] It
improves the signs and symptoms of disease in patients with active
rheumatoid arthritis (RA), PsA and axial SpA [either non-
radiographic SpA or ankylosing spondylitis (AS)], and in clinical
trials golimumab showed a high retention rate in biological-naïve
patientswithRA, PsAor SpA,with around 70%of patients still on
therapy after 5years of treatment and with sustained efficacy.[6]
However, except inRA –where the efficacy of golimumab after the
failure of other anti-TNF drugs was studied in the prospective,
controlled GO-AFTER study,[7] and a retrospective analysis of
data from the LORHEN registry[8] – information on the
effectiveness and persistence rate of golimumab as second-line
treatment is scarce. In patients with axial SpA or PsA, information
on golimumab retention rates in biological non-naïve patients
(second or further biological drug) comes from subgroups of 2
studies in different lines of therapy.[9,10]
Given the scarce information available, we focused our
research on the specific group of patients with spondyloarthro-
pathies (axial SpA or PsA) treated with golimumab as a second
biological agent. Thus, the main objective of this retrospective
study was to assess the effectiveness of golimumab as a second
anti-TNF drug in patients with SpA (either axial SpA or PsA) who
discontinued a first anti-TNF drug. In particular, the study
investigated the probability of persistence (retention rate of
treatment with golimumab, or drug survival) over time and
variables associated with higher persistence.
2. Patients and methods
2.1. Study design
The present study was an observational multicenter, longitudinal
retrospective, and noncomparative study undertaken in 20
rheumatology clinics in Spain. Data were collected for all SpA
(axial SpA or PsA) patients who had initiated golimumab as a
second biological drug (after discontinuation of a first anti-TNF
drug), between January 2013 and December 2015, according to
standard prescribing information. The diagnosis of axial SpA or
PsA was made according to clinical practice in Spain, where it is
recommended to follow the Assessment of SpondyloArthritis
International Society criteria for classification of axial SpA,[11,12]
and the Classification Criteria for Psoriatic Arthritis criteria for
PsA.[13] For patients presenting with mixed forms involving both
axial and peripheral symptoms, investigators assigned them to
the dominant group fulfilling criteria.
2.2. Ethics approval and consent to participate
The studywas approved by the Clinical Research Ethics Committee
of the Hospital Universitari of Bellvitge, L’Hospitalet de Llobregat,
Barcelona, Spain (ref EPA003/17) as reference center, and then by
the participating centers. Signed informed consent forms were
obtained from all available patients for whom data were used in the
study. Where patients could not be located to obtain consent, their
retrospective data were anonymized prior to inclusion. This was
approved by the Clinical Research Ethics Committees.
2.3. Assessment criteria
The primary objective was to assess 1-, 2- and 3-year probability
of persistence (survival on treatment, or retention rate) on
golimumab and to explore possible variables associated with
longer persistence on treatment with golimumab.
The following data were collected for stratified analyses:
gender, smoking status, age above/below median, disease
duration above/below median, axial SpA compared to PsA
patients, reason for discontinuation of first anti-TNF drug (loss of
efficacy versus other reasons), baseline C-reactive protein (CRP),
erythrocyte sedimentation rate (ESR), human leukocyte antigen
(HLA) B27 status for axial SpA patients, presence or absence of
radiographic erosions for PsA patients, prior anti-TNF drug used,
presence or absence of concomitant immune disease and the
nature of concurrent medications.
The effectiveness of golimumab was assessed at baseline and
after 3months and 1year, using the Bath Ankylosing Spondylitis
Disease Activity Index (BASDAI) for patients with axial
SpA,[14,15] and Disease Activity Score (DAS28) for patients with
PsA,[16,17] according to the available information contained in
clinical records. For patients lacking DAS28 assessment,
evolution of painful and swollen joints was recorded. In case
patients presented with axial and peripheral symptoms, effec-
tiveness was measured using the dominant disease assessment
criterion. Due to the retrospective nature of the study, flexible
windows of +/- 1month for the 3-month assessment and of +/- 3
months for the 1-year assessment were permitted.
2.4. Patient selection
Patients aged ≥18years who started golimumab for SpA as a
second anti-TNF drug between January 2013 and December
2015 were included in the study if they had been treated
successfully with a first anti-TNF drug for at least 3months (i.e.
the patient had obtained clinical benefit from a first anti-TNF
drug) and discontinued it for 1 of the following reasons:
(1) disease reactivation (loss of response or secondary failure
after the patient had responded),
(2) patient discomfort, poor tolerability or adverse event or
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(3) physician and patient agreement to substitute for patient
convenience or preference, with no therapy failure.
Patients considered to have had a primary failure to a first anti-
TNF drug (patient did not show clinical improvement on the first
anti-TNF) were excluded, as were patients who, during the
retrospective study period, participated in a clinical trial with
antirheumatic drugs.
Patients were identified in the rheumatology clinic records or
hospital pharmacy registry, and all patients fulfilling the criteria
were included in the study. All patients still on golimumab signed
informed consent before being enrolled into the study. Patients
who had already discontinued golimumab were identified,
localized and also invited to participate. For patients unable to
attend the rheumatology clinic (e.g. due to death, change of
address or other reason), anonymized data were recorded from
their clinical records. This was done to avoid bias in the
evaluation of the primary objective (probability of persistence on
golimumab). For the same reason, it was mandatory that centers
included all golimumab patients in the study, that is, patients still
receiving golimumab and those who had discontinued golimu-
mab. Centers that could not fulfil this commitment were excluded
from participation to avoid selection bias.
General demographic data, disease-related data, previous anti-
TNF drug use and reason for discontinuation, and baseline
disease activity (prior to golimumab initiation) were collected
from the clinical records. The first date of golimumab injection
and last observation date with golimumab were recorded to
assess the primary objective of the study. For patients who
permanently discontinued golimumab, the reason for discontin-
uation was classified as:
(1) primary failure (the patient never responded to golimumab),
(2) disease reactivation (secondary failure, loss of response after
golimumab was initially efficacious),
(3) poor tolerability,
(4) adverse event,
(5) inactive disease or low disease activity or
(6) other reason.
Patients who stopped golimumab temporarily (i.e. due to
infection, programmed surgery or other reason), but resumed it
successfully later on (grace period, 2months), were considered as
continuing on golimumab.
2.5. Statistical analysis
The sample size was calculated to assess the primary objective,
and due to the lack of information on persistence (retention rate)
of a second anti TNF alpha after discontinuation of a first anti
TNF alpha in spondyloarthropathies at the time of the study
design, a 50% retention rate was selected as the percentage
requiring the highest sample size. With a confidence level (level 1-
alpha) of 95% and 7% precision, the estimated sample size was
196 patients with SpA. The target sample size was increased by
15% (to 231 patients) to compensate for possible missing data.
No stratification by background disease (axial SpA versus PsA)
was done during recruitment since centers were obliged to recruit
all patients, whether or not balanced.
Summary descriptive statistics are presented as means with
standard deviations, or medians with percentiles and percentages
when applicable. The probability of persistence (drug survival)
was assessed by Kaplan-Meier analysis, for the overall popula-
tion and each background disease. Patients who were still on
golimumab at the study visit and those who had not discontinued
golimumab, but for whom data were not available from a specific
time point (due to death, emigration to other region or country,
or end of data availability for other reasons), were right-censored.
Comparisons of survival between different subgroups were
evaluated with the log-rank test. Cox-regression analyses were
performed to identify factors related to the probability of
persistence on golimumab. R Software (version 3.4.3, R Core
Team, 2017) and the RStudio interface (version 1.1.419) were
used for statistical analyses.
3. Results
3.1. Patient demographics and baseline condition
Between January 2013 and December 2015, 210 patients from 20
hospital rheumatology clinics had initiated golimumab as a second
anti-TNF drug for the treatment of axial SpA (n=131; 28 with
non-radiographic axial SpA and 103 with ankylosing spondylitis)
or PsA (n=79). Five patients from1 center (which failed to include
all golimumab patients) were excluded from all analyses.
Mean (standard deviation [SD]) age was 49.0 (12.1) years.
There were 126 men (60.0%) and 84 women (40.0%). Median
disease duration prior to golimumab initiation was 7years
(interquartile range: 3–13). Baseline characteristics of the
population are displayed in Table 1. Previous anti-TNF therapy
was etanercept (n=53, 25.2%), adalimumab (n=83, 39.5%),
infliximab (n=73, 34.8%) and certolizumab (n=1, 0.48%)
(Table 2). Reasons for discontinuation of the first anti-TNF drug
were: loss of efficacy (n=149, 71.0%), poor tolerability or
adverse event (n=24, 11.4%) and patient or physician preference
(n=37, 17.6%).
3.2. Effect of golimumab on disease activity
In axial SpA patients, mean (SD) BASDAI at baseline (n=78) was
5.5 (2.1). It was rapidly reduced to a mean of 3.9 (2.0) at month 3
and 3.5 (2.0) at year 1, and remained stable thereafter. The
percentage of patients with a BASDAI 50 response was 69.1% at
month 3 and 58.5% at year 1; the percentages with BASDAI 4
were 53.2% and 60.4%, respectively. Baseline mean (SD) CRP
(n=121) was 0.9 (1.7) mg/dL andwas reduced to 0.3 (0.6) mg/dL
at month 3 and 0.5 (1.5) mg/dL at year 1. Similarly, ESR (n=119)
decreased from baseline 22.4 (24.8) mm/h to 13.0 (12.2) and 10.8
(9.8) mm/h at month 3 and year 1, respectively.
In PsA patients, mean (SD) DAS28 (n=28) was 4.0 (1.3) at
baseline and was reduced to 2.5 (1.2) at month 3 and to 2.2 (1.3)
at year 1. The mean number of painful joints (n=59) decreased
from 4.2 (4.7) at baseline to 2.1 (2.2) and 1.1 (1.9) at month 3 and
year 1, respectively, and the mean number of swollen joints from
2.4 (2.7) to 1.3 (2.3) and 0.7 (2.0), respectively. Baseline mean
(SD) CRP (n=68) was 1.0 (2.1) mg/dL and was reduced to 0.4
(0.6) at month 3 and 0.3 (0.5) mg/dL at year 1. ESR (n=66)
decreased from 18.9 (20.0) mm/h at baseline to 14.1 (17.7) and
12.9 (13.4) mm/h at month 3 and year 1, respectively.
3.3. Probability of persistence of treatment with
golimumab
Patients were followed up for a mean (SD) period of 29.8 (16.5)
months: axial SpA patients, 30.2 (17.1) months; PsA patients,
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29.0 (16.5) months. During this period, 72 of 210 patients
(34.3%) discontinued golimumab: 39 of 131 axial SpA patients
(29.8%) and 33 of 79 PsA patients (41.8%). The probability of
persistence of treatment with golimumab (survival of golimumab
therapy) since initiation was 80% at year 1 (95% confidence
interval [CI] 75–86), 70% at year 2 (95%CI 64–77), and 65% at
year 3 and year 4 (95% CI 59–72) (Fig. 1). The probability of
persistence was slightly but non-significantly higher in patients
with axial SpA than in those with PsA (P= .121, Fig. 2A;
Supplemental Digital Content Table 1, http://links.lww.com/
MD/F975). The probability curves were very similar in patients
who discontinued their first anti-TNF due to loss of efficacy
compared with those discontinuing for other reasons (P= .750,
Fig. 2B; Supplemental Digital Content Table 2, http://links.lww.
com/MD/F976).
There were no differences in the probability of persistence by
gender (P= .313), age above/below the median (49years, p=
1.000), smoking status (P= .381), or disease duration above/
below the median (80months, P= .985).
The probability of persistence with golimumab was slightly
higher in patients with CRP values above the median (0.28mg/
dL) at the time of golimumab initiation compared to those with
values below the median (P= .175, Fig. 2C; Supplemental Digital
Content Table 3, http://links.lww.com/MD/F977), as well as in
those with ESR above the median when golimumab was started
(16mm/h) compared to those with values below the median
(P= .011, Fig. 2D; Supplemental Digital Content Table 4, http://
links.lww.com/MD/F978).
There were no differences in the probability of persistence with
regard to the HLA B27 status in patients with axial SpA, or with
regard to the presence or not of radiographic erosions in PsA
patients. The probability of persistence was higher in those
previously treated with adalimumab as first anti-TNF (continua-
tion rate at year 3: 73%) compared to in those who had stopped
infliximab (63%) or etanercept (55%), but the difference was not
statistically significant (P= .070, Figure 2e; Supplemental Digital
Content Table 5, http://links.lww.com/MD/F979).
Finally, the probability of persistence did not differ between
patients with or without other concomitant immune disease
(P= .731) and was also similar in those who were or were not
treated with glucocorticoids, nonsteroidal anti-inflammatory
drugs or non-biological disease-modifying antirheumatic drugs
(P= .710, .490, and .657, respectively). Persistence was slightly,
but non-significantly, higher (69% versus 63% at both year 3 and
year 4) in those treated with methotrexate (P= .254; Supplemen-
tal Digital Content Table 6, http://links.lww.com/MD/F980). In a
post hoc analysis, persistence with/without methotrexate in
patients with axial SpA or PsA was, in both cases, slightly but
non-significantly higher in patients treated with methotrexate
compared to those without methotrexate (P= .202 for axial SpA
patients; P= .313 for PsA patients).
Table 1






yr, mean (SD) 48.0 (12.3) 50.0 (11.7)
Gender
Male, n (%) 83 (63.4) 43 (54.4)
Female, n (%) 48 (36.6) 36 (45.6)
Duration of disease
Years, median (IQR) 8.0 (4.0–16.0) 6.0 (3.0–9.5)
Smoking habit
Never, n (%) 47 (42.3) 33 (55.9)
Current, n (%) 40 (36.0) 9 (15.3)
Past, n (%) 24 (21.6) 17 (28.8)
Not available, n 20 20
HLA B27 status
Positive, n (%) 95 (76.7) 8 (17.8)
Negative, n (%) 29 (23.4) 37 (82.2)
Not available, n 7 34
Concomitant immune-mediated diseases
Psoriasis, n (%) 12 (9.2) 38 (48.1)
Inflammatory Bowel Disease, n (%) 6 (4.6) 0 (0.0)
Uveitis, n (%) 22 (16.8) 1 (1.3)
Concomitant medication
NSAIDs 101 (77.1) 45 (57.0)
Steroids, n (%) 13 (9.9) 25 (31.7)
Non-biological DMARD 41 (31.3) 52 (65.8)
Methotrexate, n 29 36
Sulfasalazine, n 11 6
Leflunomide, n 2 13
DMARD= disease modifying antirheumatic drug, HLA= human leukocyte antigen, IQR= interquartile
range, NSAIDs = nonsteroidal antiinflammatory drugs, SD = standard deviation.
Table 2






Adalimumab, n (%) 55 (42.0) 28 (35.4)
Etanercept, n (%) 26 (19.9) 27 (34.2)
Infliximab, n (%) 50 (38.1) 23 (29.1)
Certolizumab, n (%) – 1 (1.3)
Duration of treatment with the first anti-TNF
Months, median (SD) 35.0 (10.0–73.0) 28.0 (10.5–59.0)
Reason for discontinuation
Loss of efficacy (disease reactivation), n (%) 98 (74.8) 51 (64.5)
Adverse event or intolerance, n (%) 11 (8.4) 13 (16.5)
Patients and/or physician preference, n (%) 22 (16.8) 15 (19.0)
SD = standard deviation, TNF= tumor necrosis factor.
Figure 1. Probability of persistence with golimumab treatment in all patients.
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3.4. Multivariate analysis
Cox-regression analysis including CRP and ESR showed that
patients with ESR above themedian at golimumab initiation were
less likely to discontinue golimumab than those below themedian
(hazard ratio [HR], 0.59, 95%CI 0.36–0.95; P= .031). CRP was
not statistically related to discontinuation of golimumab in this
model (Table 3).
A second model, including as predictive variables age, gender,
methotrexate use and those variables with P-values .2 in the
bivariate analysis (diagnosis, previous anti-TNF drug, CRP and ESR
whengolimumabwas started), showed thatpatientswhohadstopped
treatment with adalimumab had a lower probability of discontinua-
tion of golimumab therapy than those previously treated with
etanercept (HR,0.28,P= .012). Similarly, patientswithaxial SpAhad
a lower probability of discontinuation of golimumab therapy
compared to PsA patients (HR, 0.44, P= .063) [Table 3, Model 2].
3.5. Reasons for discontinuation of golimumab
Overall, 72 of 210 patients (34.3%) discontinued golimumab
during the follow-up. The reasons for discontinuation were
primary failure (n=21), disease reactivation or secondary failure
(n=29), poor tolerability (n=4), adverse events (n=10) and
patient-physician agreement due to inactive disease or low
disease activity (n=8). Reasons for discontinuation did not differ
between patients with axial SpA or those with PsA.
4. Discussion
Previous observational studies have described the golimumab
retention rate in SpA patients previously treated with other
biological drugs as subgroups of larger cohorts without stratifying
non-naïve patients in second or further lines of therapy.[9,10] Our
study assessed, specifically, the effectiveness and persistence
(survival on therapy or retention rate) of golimumab as a second
anti-TNF drug in patients with SpA (axial SpA or PsA) who had
discontinued a first anti-TNF drug,with up to 4years of follow-up.
Golimumab was effective for the treatment of these patients in the
short term, reducing disease activity (BASDAI and DAS28) and
inflammatory markers (CRP and ESR). In the long term,
there was a high rate of retention of golimumab therapy (65%)
after 3–4years. Golimumab showed similar short-term effective-
Figure 2. Probability of persistence with golimumab treatment in patients (A) diagnosed with axial SpA (red) or PsA (blue); (B) discontinuing the first anti-TNF drug
for loss of efficacy (red) versus for other reasons (blue); (C) whose baseline C-reactive protein (CRP) level was over (red) or under (blue) the median value; (D) whose
baseline erythrocyte sedimentation rate (ESR) level was over (red) or under (blue) themedian value; (E) treated with adalimumab (red), etanercept (green) or infliximab
(blue) as first anti-TNF drug.
Table 3








ESR (above vs below the median) 0.59 0.36–0.95 .031
CRP (above vs below the median) 0.74 0.48–1.19 .217
Model 2
Gender (women vs men) 0.58 0.25–1.34 .206
Age (above vs below the median) 1.68 0.75–3.76 .208
Diagnosis (axial SpA vs PsA) 0.44 0.18–1.05 .063
Previous anti-TNF (adalimumab vs etanercept) 0.28 0.10–0.76 .012
Previous anti-TNF (infliximab vs etanercept) 0.45 0.18–1.16 .098
Use of methotrexate (yes vs no) 0.55 0.25–1.23 .145
ESR (above vs below the median) 0.53 0.24–1.19 .123
CRP (above vs below the median) 0.60 0.26–1.37 .225
CRP=C-reactive protein; ESR= erythrocyte sedimentation rate; PsA=psoriatic arthritis; SpA=
spondyloarthritis; TNF= tumor necrosis factor.
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ness in patients with axial SpA or PsA, but long-term persistence
seemed better in patients with axial SpA.
The clinical development of golimumab comprised clinical
trials in patients with RA, axial SpA and PsA who had failed
conventional non-biological treatment, including disease-modi-
fying antirheumatic drugs (methotrexate), in RA. For patients
with RA (but not axial SpA or PsA), clinical trials also considered
patients who had failed on previous biological medication. Thus,
the current study provides specific information on the effective-
ness of golimumab in a subset of patients who had not been
included in clinical trials, and suggests that, in patients with
spondyloarthropathies who need to discontinue using a first anti-
TNF, switching to golimumab is a suitable option.
A review of English-language publications of clinical trials
which reported on the efficacy of second-line biologicals
concluded that, for PsA and AS patients failing a first anti-
TNF drug, switching to a second is advisable.[18] Indeed, after the
failure of a first anti-TNF, therapeutic guidelines describe the
option of switching to another biological drug; either another
anti-TNF or a drug with a different mechanism of action.[2–4] In
particular, the recently updated 2019 American College of
Rheumatology, Spondylitis Association of America and Spon-
dyloarthritis Research and Treatment Network guidelines
conditionally recommend a second anti-TNF after discontinua-
tion of a first anti-TNF due to secondary nonresponse in axial
spondyloarthritis, although with a very low level of evidence.[2]
For patients with primary nonresponse, the guidelines recom-
mend switching to a drug with another mechanism of action, also
with a very low level of evidence.[2] Thus, data on the
effectiveness of different biologicals after discontinuation of
one anti-TNF drug are welcome. Recent research indicates that
therapeutic drug monitoring (TDM) with serum level measure-
ment and antidrug antibody detection could potentially be a
useful tool for the individualization of biological therapy[19–21]
and selection of a second or subsequent biological drug.
In the present study, probabilities of persistence with
golimumab as a second anti-TNF drug in SpA patients were
high and at least as good as data reported with other anti-TNF
drugs, whether as first-line or subsequent lines of anti-TNF
therapy. Among 990 anti-TNF treatment courses (with adali-
mumab, infliximab, etanercept or golimumab) as first, second or
third anti-TNF in 765 patients with PsA treated in Finland
between 2004 and 2014, the probability of persistence was 80%
at 1year and 72% at 2years.[22] The probability of discontinua-
tion of anti-TNF drug was similar whether it was the first or a
subsequent drug.[22] Similarly, in a review of randomized
controlled trials of anti-TNF drugs for axial SpA or AS (but
mostly AS), across all anti-TNF drugs, drug survival was 70% to
80% after 1year, 65% to 75% after 2years and 55% at 5
years.[23] In AS patients, across all anti-TNF drugs, median drug
survival was 3.1years for a first anti-TNF drug, 1.6years for a
second and 1.8years for a third; 2-year drug survival was 58%,
47%, and 49%, respectively (based on data from the Danish
nationwide DANBIO registry[24]).[23] In contrast, in a longer-
term analysis of patients with axial SpA receiving anti-TNF drugs
at 2 specialist centers in the UK, median drug survival was 10.2
years for the first or index anti-TNF drug (n=651) and 5.5years
for a second anti-TNF drug after switching from the index drug
(n=105). Drug survival was not influenced by the choice of anti-
TNF drug.[25]
With regard to studies which have focused on golimumab, a
retrospective, observational study in Greece involving 328
patients, reported drug survival rates with golimumab after 3
years of 76% in AS patients, 60% in RA patients, and 53% in
PsA patients.[26] Regarding the use of golimumab as a second
anti-TNF, a recent retrospective analysis of data from the
LORHEN registry showed that the 2-year retention rate was
higher with golimumab than with etanercept or adalimumab
(53.4%, 39.8%, and 31.2%, respectively), and there was a lower
discontinuation rate due to adverse events in patients treated with
golimumab.[8] Iannone et al described 2-year persistence rates of
67.3% and 72.2% for the overall naïve and non-naïve arthritis
population, with no differences for patients with axial SpA or
PsA,[9] and recently Michelsen et al. reported a 4-year retention
rate of around 30% in non-naïve golimumab patients,[10] but
they did not stratify by second or further line of therapy. Finally, a
retrospective analysis of the Spanish Registry of Biological Drugs
in Rheumatic Diseases reported high continuation rates of
golimumab as a second biological drug in rheumatic diseases up
to 4years of follow-up (up to 59.2% at year 4) including a small
sample of patients with axial SpA (n=52) or PsA (n=33).[27]
Interestingly, in the current study, golimumab seemed to be
similarly effective in patients who discontinued the first anti-TNF
drug due to loss of efficacy compared with in those who
discontinued for other reasons. Others have also reported no
difference in survival analysis with a second anti-TNF drug
according to reason for discontinuation of the first anti-TNF
drug.[10] This finding supports the use of golimumab in these
patients after failure or discontinuation of a first anti-TNF drug
independently of the reason, except when discontinuation was
due to primary nonresponse. Higher retention of golimumab was
seen in patients with higher CRP or, significantly, higher ESR
levels. These patients, with higher markers of inflammation at
baseline, would seem better suited for obtaining clinical benefit
from anti-TNF drugs. It has previously been shown that increased
CRP levels and higher BASDAI scores are valuable predictors of
clinical response to anti-TNF drugs.[28] In the GO-AHEAD study,
the benefits of golimumab were not apparent in patients with
normal CRP and no inflammatory signs by magnetic resonance
imaging.[29] In the present study, mean CRP was relatively low
because all patients had been previously treated with a biological
drug and because up to 29% of patients were discontinued for
reasons other than disease reactivation.
The higher probability of continuation with golimumab in
patients who had received adalimumab compared with that in
patients who had previously received other anti-TNF drugs
requires further investigation with a larger sample of patients.
The slightly better persistence seen with golimumab when used in
combination with methotrexate is consistent with earlier
reports.[30]
Possible explanations for these high retention rates with
golimumab as a second anti-TNF could relate to the convenience
of a once-monthly, self-administered medication,[22] and/or the
fact that the drug was well tolerated (only 6.7% of patients
discontinued golimumab for poor tolerability or adverse effects in
the present study). From some studies it appears that, due to the
molecular characteristics of golimumab, there is a lower
frequency of anti-drug antibody formation,[21] and this may
also contribute to the good retention rate of golimumab as a
second biological drug. Because persistence with the same anti-
TNF drug in second-line treatment decreases the overall disease-
associated costs compared with non-persistence, this aspect also
merits consideration by physicians and payers when choosing a
biological drug.[31]
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There were a number of limitations to this study. Because data
were collected retrospectively, disease activity (BASDAI and DAS
28) was not reported adequately in the clinical records for all
patients. Functional and motion activity indexes (Bath Ankylos-
ing Spondylitis Functional Index, Bath Ankylosing Spondylitis
Metrology Index), and other currently important activity indices
like Ankylosing Spondylitis Disease Activity Score or Disease
Activity for Psoriatic Arthritis, were not reported in the clinical
records, so accurate information on disease evolution was
limited. Similarly, data to calculate currently used indices, such as
minimal disease activity in PsA, were also lacking, and body mass
index data, an important variable, were not collected in many
clinical records and, therefore, could not be analyzed. Previous
studies have shown a relationship between overweight and
obesity with poorer clinical outcomes and lower retention rate of
biological drugs,[32,33] but unfortunately we could not analyze
the impact of body mass index in our study. As real-world data
are becoming indispensable for understanding the effectiveness of
drugs in different populations and guiding the best therapeutic
decisions, standardization of data collection among different
clinics or regions/countries is needed to facilitate obtaining this
important information more accurately. The absence of
radiographic analysis meant that it was not possible to confirm
whether the clinical effectiveness of golimumab in these patients
was associated with reduced radiographic damage or progres-
sion. Also, whilst we considered some predictive factors, it would
be interesting for future research to assess other aspects such as
the type of arthritis in PsA (e.g. polyarthritis or oligoarthritis,
enthesitis), psoriasis severity, extra-articular involvement such as
uveitis or inflammatory bowel disease, and other comorbidities,
for which a larger sample size of patients will be needed. In this
case, the sample size was limited, precluding the identification of
stronger associations. In particular, the influence of methotrexate
on long-term effectiveness cannot be ruled out.
Changing from 1 biological drug to another has been reported
to be associated with an increase in treatment costs.[31,34]
Nonetheless, treatment switching is required (and recommended)
where there is treatment failure or intolerance. Except for patients
with primary nonresponse to anti-TNF drugs, starting a second
anti TNF drug is supported by current recommendations.[2–4]
Choosing a subsequent anti-TNF drug with a high survival or
persistence rate is, therefore, an important factor in the
economics of patient management for patients with rheumatic
disease. Golimumab was effective and showed a high probability
of persistence as a second anti-TNF drug in patients with SpA
who need to discontinue the use of a first anti-TNF drug for
reasons other than primary nonresponse.
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